ArriVent BioPharma (AVBP) shares plummeted 5.12% in Tuesday's trading session, as investors grappled with conflicting analyst reports. The significant drop comes as Wall Street analysts provided divergent views on the company's future prospects, leaving investors uncertain about the stock's trajectory.

Citigroup dealt a blow to ArriVent BioPharma by cutting its target price from $40 to $33. This bearish stance suggests that Citigroup analysts have become more pessimistic about the company's near-term outlook. The downward revision in the target price likely contributed to the selling pressure on AVBP stock.

In contrast, H.C. Wainwright took a more optimistic view, raising its target price for ArriVent BioPharma from $40 to $42. Despite this positive adjustment, it appears that investors were more swayed by Citigroup's bearish outlook. The stark difference in analyst opinions highlights the current uncertainty surrounding ArriVent BioPharma's future performance and may have prompted some investors to reduce their positions, leading to the sharp decline in stock price.